Annovis Bio, a biotech company developing treatments for neurodegenerative diseases, received a notice from the NYSE for failing to meet continued listing standards because its average market capitalization and stockholders' equity fell below $50 million. The company has 45 days to submit a plan to regain compliance within nine months. If accepted, Annovis' stock will remain listed with a '.BC' designation indicating below-standard status. Failure to comply may lead to delisting. This notice does not affect the company's operations or SEC reporting obligations.
Annovis Bio, Inc. received a continued listing standard notice from the NYSE. For readers following the health sector, here is Pluang's market snapshot as of Oct 31, 2026 03:11 WIB: out of 150 priced US health stocks, 51 rose and 99 fell. Notable movers include Bruker Corporation at USD 57.13 with a 1-day change of -7.85%, Maravai LifeSciences at USD 7.80 down 7.74%, and Hims and Hers Health at USD 27.59 with 85% sell order activity.
3E Network Technology Group Limited received a notice from Nasdaq that its Class A shares will be delisted due to the share price falling below $1.00 for 30 consecutive business days. The company is not eligible for a compliance period because of a r...
Philips has introduced the HyperVue Integrated System in the U.S., a fixed, single-room setup combining DeepOCT+NIRS imaging with X1-FFR physiology assessment for coronary interventions. This system is designed to streamline cath lab workflows by kee...
Atlas Copco Group completed Expansion Week in the US, unveiling three major manufacturing expansions in New York and South Carolina. The new facilities will increase production of oil-free compressors, dry vacuum pumps, and gas and process equipment,...
Mohawk Industries reported Q3 2026 net sales of $2.8 billion, up about 1%, driven by price increases offsetting lower volumes amid weak demand. Adjusted EPS rose 2% to $2.72, supported by productivity and pricing strategies. The company generated $39...
The global Drone as First Responder (DFR) market, valued at $3 billion in 2025, is projected to grow to $11 billion by 2033 at a 17.7% CAGR. Growth is fueled by advancements in automated drone-in-a-box systems, beyond visual line of sight (BVLOS) ope...
